Kröger N., Gribben J., Chabannon C., Yakoub-Agha I., Einsele H. (eds.) The EBMT/EHA CAR-T Cell Handbook

Springer, 2022. — 221 p. — ISBN 978-3-030-94352-3.This first European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.The Science Behind CAR-T Cells
Structure of and Signalling Through Chimeric Antigen Receptor
Genetic Engineering of Autologous or Allogeneic Immune Effector Cells
What Defines a Good Tumour Antigen?​
Tumour Escape from CAR-T Cells
CART Initiatives in Europe
Manufacturing CAR-T Cells: The Supply Chain
Providing the Starting Material to the Manufacturer of an Approved and Commercially Available Autologous CAR-T Cell Treatment
Receiving, Handling, Storage, Thawing, Distribution, and Administration of CAR-T Cells Shipped from the Manufacturing Facility
Point-of-Care Production of CAR-T Cells
Off-the-Shelf Allogeneic CAR-T Cells or Other Immune Effector Cells
Clinical Indications for CAR-T Cells
Paediatric Acute Lymphoblastic Leukaemia (ALL)
Adult Acute Lymphoblastic Leukaemia
Diffuse Large B Cell Lymphoma and Primary Mediastinal Lymphoma
Mantle Cell Lymphoma
Chronic Lymphocytic Leukaemia
Indolent Lymphomas
Multiple Myeloma
Developments in Other Haematological Malignancies:​ Other Lymphoid Malignancies
Myeloid Malignancies
Developments in Solid Tumours
Clinical Management of Patients Treated with CAR-T CellsBridging Chemotherapy:​ Adult Acute Lymphoblastic Leukaemia
Bridging to CAR-T Cells in Children, Adolescents, and Young Adults with ALL
Bridging Chemotherapy:​ Relapsed/​Refractory Aggressive B-Cell Lymphoma
Bridging Chemotherapy:​ Follicular Lymphoma, Mantle Cell Lymphoma, and CLL
Bridging Chemotherapy:​ Multiple Myeloma
Lymphodepleting Conditioning Regimens
Management of Cytokine Release Syndrome (CRS) and HLH
Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Management of Hypogammaglobuli​naemia and B-Cell Aplasia
Management of Myelotoxicity (Aplasia) and Infectious Complications
Management of Other Toxicities
ICU
Post-CAR-T Cell Therapy (Consolidation and Relapse):​ Acute Lymphoblastic Leukaemia
Post-CAR-T Cell Therapy (Consolidation and Relapse):​ Lymphoma
Post-CAR-T Cell Therapy (Consolidation and Relapse):​ Multiple Myeloma
Immune Monitoring
Long-Term Follow-Up and Late Effects
Access to CAR-T Cells
The Regulatory Framework for CAR-T Cells in Europe:​ Current Status and Foreseeable Changes AND Centre Qualification by Competent Authorities and Manufacturers
How Can Accreditation Bodies, Such as JACIE or FACT, Support Centres in Getting Qualified?​
Educational Needs for Physicians
Education Needs for Nurses in Adult and Paediatric Units
Role of Pharmacists
Educational Needs for Cell Processing Facility Personnel
GoCART
Patient Referral
Treatment Coverage and Reimbursement
The Value of CAR-T-cell Immunotherapy in Cancer
What do Patients Want?​ The Importance of Patient-reported Outcomes